Impurity testing of ranitidine products: US FDA update

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1779卷 / 1期

关键词：

D O I：

10.1007/s40278-019-71265-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：1 / 1

相关论文

共 50 条

[11] US FDA calls for antidepressant 'black box' update
Reactions Weekly, 2007, 1151 (1) : 3 - 3
[12] US FDA issues reminder to update NSAID labelling
Reactions Weekly, 2005, 1057 (1) : 3 - 3
[13] FDA Update: Improving Access to Biosimilar Drug Products
Demler, Tammie Lee
US PHARMACIST, 2021, 46 (06) : 39 - 42
[14] How to comply with FDA-imposed nitrosamine impurity testing
Walker, Michael
Manufacturing Chemist, 2020, 91 (06): : 32 - 34
[15] Patient In-Use Stability Testing of FDA-Approved Metformin Combination Products for N-Nitrosamine Impurity
Sathish Dharani
Eman M. Mohamed
Ziyaur Rahman
Mansoor A. Khan
AAPS PharmSciTech, 25
[16] Patient In-Use Stability Testing of FDA-Approved Metformin Combination Products for N-Nitrosamine Impurity
Dharani, Sathish
Mohamed, Eman M.
Rahman, Ziyaur
Khan, Mansoor A.
AAPS PHARMSCITECH, 2024, 25 (01)
[17] CIMETIDINE USE IN US: EFFECTS OF FDA WITHDRAWAL OF RANITIDINE AND COVID-19 PANDEMIC
Balaban, David H.
McNamara, Sherrie
Galt, Deborah J.
GASTROENTEROLOGY, 2021, 160 (06) : S449 - S449
[18] US FDA provides update on CardioGen-82 safety
Reactions Weekly, 2012, 1386 (1) : 4 - 4
[19] US FDA strengthens renal warnings for diabetes products
Reactions Weekly, 2016, 1607 (1) : 6 - 6
[20] FDA UPDATE - DISSOLUTION TESTING - SIMPLE TOOL - IMPORTANT CONTRIBUTION
SKELLY, JP
GONZALEZ, MA
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1993, 39 (05) : 222 - 223

← 1 2 3 4 5 →